On May 28, 2025 Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developing advanced cancer therapeutics and drug delivery technologies, reported that its Chief Executive Officer and Chief Operating Officer will be attending the prestigious BIO International Convention, taking place in Boston from June 16-19, 2025 (Press release, Defence Therapeutics, MAY 29, 2025, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-to-attend-bio-international-convention-in-boston-june-2025 [SID1234653484]). This event brings together global leaders in biotechnology and pharmaceuticals, providing a unique opportunity for Defence to engage with key stakeholders and showcase its innovative technologies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The BIO International Convention is recognized as the largest and most comprehensive event in the biotechnology sector, attracting over 20,000 industry leaders from around the world. The conference serves as a vital platform for networking, fostering collaborations, and exploring investment opportunities. The event offers invaluable opportunities for both chance encounters and pre-scheduled meetings with investors, partners, and collaborators, making it an essential event for companies seeking to expand their reach and impact within the biotech and pharma industries.
At this year’s convention, Defence will highlight the significant potential of its Accum technology, designed to enhance the efficacy of antibody-drug conjugates ("ADCs") and improve tumor-killing capabilities—even with ADCs previously considered to have limited therapeutic potential. By participating in BIO 2025, Defence seeks to advance discussions with prospective partners and investors, furthering its mission to deliver next-generation cancer therapies.